Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Bosulif (bosutinib — CML) — U.S. revenues by Year
Bosulif (bosutinib — CML) — U.S. revenues ($M) ($M)
Pfizer Bosulif (bosutinib — CML) — U.S. revenues: $488M in FY2025, up 6.1% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
“|| Bosulif | 611 | 645 | (5%) | (5%) | 488 | 460 | 6% | 124 | 185 | (33%) | (34%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up bosulif (bosutinib — CML) — U.S. revenues
Cite this data
StockData. (2026). Pfizer Bosulif (bosutinib — CML) — U.S. revenues ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/bosulif-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.